Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
05/17/18
Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY. The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for ... 
05/09/18
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
– Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma planned for later this year – – FDA dialogue ongoing to support development of SER-287 for Ulcerative Colitis; Company plans to initiate clinical trial in mid-2018 – – Company to host Microbiome R&D Day on May 24 in New York City – ... 
05/07/18
Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 9, 2018 at 8:30 a.m. ET to discuss first quarter 2018 financial results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1599207. ... 
EventsMore
Webcast ImageWebcast
Seres Therapeutics, Inc. at the Bank of America Merrill Lynch 2018 Health Care Conference (Replay)
05/17/18 at 8:55 a.m. PT
Seres Therapeutics, Inc. at the Bank of America Merrill Lynch 2018 Health Care Conference
Thursday, May 17, 2018 8:55 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Seres Therapeutics, Inc. to host a Microbiome R&D Day (Live)
05/24/18 at 8:00 a.m. ET
Seres Therapeutics, Inc. to host a Microbiome R&D Day
Thursday, May 24, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download DocumentationCorporate Presentation

DateTitleRemind
Me
Prior to
Event
05/24/18 8:00 a.m. ET
Seres Therapeutics, Inc. to host a Microbiome R&D Day
days
Enter your e-mail address 
Stock Quote
NASDAQ:MCRB
$8.10
 + 0.12 (1.50%)
05/23/18 10:12 a.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.